comparemela.com

Latest Breaking News On - Patients beyond - Page 21 : comparemela.com

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,.

Australia
Shanghai
China
United-states
Hong-kong
Singapore
Beijing
Illinois
South-korea
Chicago
American
Kevin-lynch

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,.

Australia
Shanghai
China
United-states
Hong-kong
Singapore
Beijing
Illinois
South-korea
Chicago
American
Kevin-lynch

Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018

Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Australia
Bo-shan
Shandong
Shanghai
Hong-kong
South-korea
Singapore
Kevin-lynch
Asia-pacific
Company-annual
Antengene-corporation

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,.

China
Australia
Bo-shan
Shandong
Hong-kong
South-korea
Singapore
Asia-pacific
Peter-qian
Company-annual
Antengene-corporation
Hong-kong-stock-exchange

Antengene's Pivotal "MARCH" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

- Results showed an overall response rate (ORR) of 29.3% for all treated patients.- Consistent responses across all risk groups, including patient.

China
Australia
Shanghai
Hong-kong
South-korea
Singapore
Chinese
Kevin-lynch
Asia-pacific
Peter-qian
Company-annual
Antengene-corporation

vimarsana © 2020. All Rights Reserved.